Refused by a doctor for not being overweight, she got doses from an acquaintance and spent two days ill. She writes about why she wanted to be thinner anyway.
Recap by typeshit. Full story at The i Paper.
A systematic review cited by Dr. Axe found human safety data on BPC-157 comes from just 30 people, a thin base for a widely used peptide.
A short post from the endocrinologist pushing back on headlines tying the eye condition to GLP-1 drugs, urging people to look at the data.
A brief post notes growing concern over reports of serious eye problems in people taking Ozempic and similar drugs, while research into the link continues.
Mounjaro became India's top-selling drug in 2025, and a Scroll investigation reports that pharmacies are handing it out without the prescription it requires.
Traders Union looks at whether Novo Nordisk shares can hold their gains, pointing to the Wegovy pill approval and recent trial data.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Loading…